The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Sarcoidosis Market During The Forecast Period 2026–2030?
The sarcoidosis market size has experienced rapid expansion in recent years. It is anticipated to grow from $34.37 billion in 2025 to $39.72 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.6%. This historical growth can be attributed to factors such as the enduring reliance on corticosteroids as a first-line therapy, an increase in the diagnosis of pulmonary sarcoidosis, rising awareness among pulmonologists and rheumatologists, gradual improvements in diagnostic imaging techniques, and the limited availability of approved targeted therapies.
The sarcoidosis market is projected to experience substantial expansion over the coming years, with its size forecast to reach $69.92 billion by 2030, driven by a compound annual growth rate (CAGR) of 15.2%. This anticipated growth can be attributed to several factors, including the development of new biologics and immunomodulating agents, a heightened emphasis on therapeutic approaches that reduce steroid dependence, an increasing incidence of chronic and systemic sarcoidosis, broadened clinical investigation into uncommon inflammatory conditions, and enhanced patient access to specialized medical facilities. During the forecast period, significant trends are expected to involve a rise in the off-label application of biologics for difficult-to-treat sarcoidosis, a sharpened focus on managing sarcoidosis affecting the lungs, wider acceptance of corticosteroid-reducing treatment plans, more frequent utilization of imaging techniques and biomarkers for tracking disease progression, and an increase in clinical trials evaluating innovative anti-inflammatory treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23508&type=smp
Which Economic Or Industry Drivers Are Impacting The Sarcoidosis Market?
The sarcoidosis market is anticipated to expand due to a rising emphasis on personalized medicine in the future. This advanced medical treatment methodology customizes therapeutic plans for individual patients, considering their genetic makeup, biomarkers, environmental elements, and lifestyle, thereby guaranteeing more accurate, potent, and focused interventions. Demand for personalized medicine is increasing because it enables treatments to be adapted to an individual’s genetic and biological profile, leading to improved efficacy and fewer adverse effects. Within sarcoidosis, personalized medicine customizes treatment by leveraging genetic, biomarker, and clinical profiling to boost effectiveness and minimize adverse reactions. This method strengthens targeted therapies, dealing with the diverse nature of the disease and varied patient responses. For example, data from February 2024, provided by the Personalized Medicine Coalition, a US-based nonprofit organization, indicates that the U.S. Food and Drug Administration (FDA), a US-based government regulatory agency, sanctioned 16 new personalized treatments for individuals with rare diseases in 2023, marking a substantial rise from the 6 personalized treatments approved in 2022. Consequently, the heightened attention on personalized medicine is propelling the expansion of the sarcoidosis market.
What Market Segments Are Evaluated Within The Sarcoidosis Market?
The sarcoidosis market covered in this report is segmented –
1) By Type: Pulmonary Sarcoidosis, Ocular Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoidosis, Musculoskeletal Sarcoidosis, Cutaneous Sarcoidosis, Renal Sarcoidosis, Hepatic Sarcoidosis, Sarcoidosis Of The Spleen And Bone Marrow
2) By Diagnostic Method: Imaging Technique, Biopsy, Blood Tests
3) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Biologics, Anti-Malarial Drugs
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End Uses: Hospitals And Clinics, Surgical Centers, Diagnostic Centers, Other End Uses
Subsegments:
1) By Pulmonary Sarcoidosis: Acute Pulmonary Sarcoidosis, Chronic Pulmonary Sarcoidosis, Fibrotic Pulmonary Sarcoidosis
2) By Ocular Sarcoidosis: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis, Optic Neuropathy
3) By Neurosarcoidosis: Meningeal Neurosarcoidosis, Cranial Nerve Neurosarcoidosis, Peripheral Neuropathy, Spinal Cord Involvement, Hypothalamic-Pituitary Involvement
4) By Cardiac Sarcoidosis: Atrioventricular Block, Ventricular Arrhythmias, Heart Failure, Myocarditis, Sudden Cardiac Arrest
5) By Musculoskeletal Sarcoidosis: Arthritis, Myopathy, Bone Lesions
6) By Cutaneous Sarcoidosis: Lupus Pernio, Erythema Nodosum, Papular Sarcoidosis, Plaque Sarcoidosis, Subcutaneous Sarcoidosis
7) By Renal Sarcoidosis: Granulomatous Interstitial Nephritis, Nephrocalcinosis, Hypercalciuria-Induced Kidney Disease
8) By Hepatic Sarcoidosis: Granulomatous Hepatitis, Portal Hypertension, Hepatic Fibrosis
9) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly, Pancytopenia, Bone Marrow Granulomas
Which Trends Are Shaping The Future Of The Sarcoidosis Market?
Companies operating within the sarcoidosis market are actively pursuing the development of innovative products, such as anti-TNFa monoclonal antibody therapy, with the goal of introducing a novel biologic treatment to address crucial unmet medical requirements in managing inflammatory diseases. Anti-tumor necrosis factor-alpha (anti-TNFa) monoclonal antibody therapy functions as a targeted immunotherapy, employing monoclonal antibodies to inhibit TNFa, a pro-inflammatory cytokine, thereby mitigating inflammation and aiding in the management of autoimmune diseases. For instance, in November 2023, Xentria, Inc., a US-based clinical-stage biotherapeutics company, achieved a significant milestone when its principal candidate, XTMAB-16, received Orphan Drug Designation from the European Medicines Agency (EMA). Concurrently, the company commenced its global clinical study for pulmonary sarcoidosis by enrolling the initial patient. XTMAB-16, a monoclonal antibody that targets tumor necrosis factor-alpha (TNFa), is currently being investigated for its capability to modulate inflammatory pathways in pulmonary sarcoidosis, offering a focused alternative to corticosteroid-based therapies. This recognition from regulatory bodies and the advancement in clinical trials underscore the increasing worldwide attention on innovative biologics for rare diseases, strengthening Xentria’s dedication to meeting unmet medical needs with transformative treatment solutions.
Who Are The Top Market Participants Influencing The Sarcoidosis Market?
Major companies operating in the sarcoidosis market are Pfizer Inc, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc, UCB Pharma, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Lupin Limited, Mallinckrodt Pharmaceuticals, Xentria Inc, Molecure SA, Relief Therapeutics Holding AG, Sanofi SA, Amgen Inc, Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd
Read the full sarcoidosis market report here:
https://www.thebusinessresearchcompany.com/report/sarcoidosis-global-market-report
What Are The Top-Performing Regions Within The Sarcoidosis Market?
Europe was the largest region in the sarcoidosis market in 2025. The regions covered in the sarcoidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Sarcoidosis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23508&type=smp
Browse Through More Reports Similar to the Global Sarcoidosis Market 2026, By The Business Research Company
Mucolipidosis Ii Global Market Report
https://www.thebusinessresearchcompany.com/report/mucolipidosis-ii-global-market-report
Psoriasis Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Sarcopenia Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model